MXPA05006975A - Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa. - Google Patents
Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa.Info
- Publication number
- MXPA05006975A MXPA05006975A MXPA05006975A MXPA05006975A MXPA05006975A MX PA05006975 A MXPA05006975 A MX PA05006975A MX PA05006975 A MXPA05006975 A MX PA05006975A MX PA05006975 A MXPA05006975 A MX PA05006975A MX PA05006975 A MXPA05006975 A MX PA05006975A
- Authority
- MX
- Mexico
- Prior art keywords
- phosphodiesterase
- compounds
- inhibitory activity
- activity against
- adrenergic receptors
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 title 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 title 1
- 230000003177 cardiotonic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000004094 calcium homeostasis Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43552402P | 2002-12-23 | 2002-12-23 | |
| PCT/US2003/041031 WO2004058726A2 (en) | 2002-12-23 | 2003-12-23 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05006975A true MXPA05006975A (es) | 2005-12-14 |
Family
ID=32682255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05006975A MXPA05006975A (es) | 2002-12-23 | 2003-12-23 | Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070117978A1 (https=) |
| EP (1) | EP1575923A2 (https=) |
| JP (1) | JP2006513222A (https=) |
| AU (1) | AU2003300297A1 (https=) |
| CA (1) | CA2511496A1 (https=) |
| MX (1) | MXPA05006975A (https=) |
| WO (1) | WO2004058726A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050657A2 (en) * | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| JP2008521806A (ja) * | 2004-11-30 | 2008-06-26 | アーテシアン セラピューティクス， インコーポレイテッド | 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物 |
| US20080255134A1 (en) * | 2004-11-30 | 2008-10-16 | Artesian Therapeutics, Inc. | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase |
| JP2009506123A (ja) | 2005-08-29 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン |
| EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
| WO2007027594A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| CN102223882B (zh) * | 2008-11-25 | 2016-02-03 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂 |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5283382A (en) * | 1975-12-27 | 1977-07-12 | Otsuka Pharmaceut Co Ltd | Synthesis of carbostyril derivatives |
| DE2609645A1 (de) * | 1976-03-09 | 1977-09-15 | Boehringer Sohn Ingelheim | Aminoalkylheterocyclen |
| DE2644833A1 (de) * | 1976-10-05 | 1978-04-20 | Boehringer Sohn Ingelheim | Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung |
| DE3023369A1 (de) * | 1980-06-23 | 1982-01-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU565621B2 (en) * | 1983-04-26 | 1987-09-24 | Smithkline Beckman Corporation | Dopaminergic carbostyrils |
| JPS6193169A (ja) * | 1984-10-12 | 1986-05-12 | Sankyo Co Ltd | ピリダジノン誘導体及びその製法 |
| GB8528633D0 (en) * | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| DK391189A (da) * | 1988-08-10 | 1990-02-11 | Otsuka Pharma Co Ltd | Carbostyrilderivater |
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JP2931635B2 (ja) * | 1989-06-19 | 1999-08-09 | 帝国臓器製薬株式会社 | ピリダジノン化合物 |
| NZ234087A (en) * | 1989-06-19 | 1991-08-27 | Teikoku Hormone Mfg Co Ltd | 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives |
| CA2027863A1 (en) * | 1989-11-20 | 1991-05-21 | George Sachs And Jai Moo Shin Partnership Of Michael E. Garst | Anti-inflammatory furanone compounds |
| TW201305B (https=) * | 1991-04-03 | 1993-03-01 | Otsuka Pharma Co Ltd | |
| JPH05283382A (ja) * | 1992-03-31 | 1993-10-29 | Murata Mfg Co Ltd | 半導体ウェハの裏面加工方法及び裏面加工時における半導体ウェハの表面側構造 |
| US5641783A (en) * | 1993-11-12 | 1997-06-24 | Cell Therapeutics, Inc. | Substituted amino alcohol compounds |
| US5827893A (en) * | 1996-03-29 | 1998-10-27 | Lurie; Keith G. | Mechanical and pharmacological therapies to treat cardiac arrest |
| WO1998010765A1 (en) * | 1996-09-13 | 1998-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
| NZ522882A (en) * | 2000-06-05 | 2004-07-30 | Altana Pharma Bv | Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| WO2004050657A2 (en) * | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
-
2003
- 2003-12-23 US US10/547,930 patent/US20070117978A1/en not_active Abandoned
- 2003-12-23 AU AU2003300297A patent/AU2003300297A1/en not_active Abandoned
- 2003-12-23 CA CA002511496A patent/CA2511496A1/en not_active Abandoned
- 2003-12-23 EP EP03814338A patent/EP1575923A2/en not_active Withdrawn
- 2003-12-23 MX MXPA05006975A patent/MXPA05006975A/es unknown
- 2003-12-23 WO PCT/US2003/041031 patent/WO2004058726A2/en not_active Ceased
- 2003-12-23 JP JP2004563978A patent/JP2006513222A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006513222A (ja) | 2006-04-20 |
| AU2003300297A1 (en) | 2004-07-22 |
| WO2004058726A3 (en) | 2004-10-28 |
| WO2004058726A2 (en) | 2004-07-15 |
| EP1575923A2 (en) | 2005-09-21 |
| CA2511496A1 (en) | 2004-07-15 |
| US20070117978A1 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006060122A3 (en) | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | |
| MXPA05006975A (es) | Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa. | |
| NZ544591A (en) | Pyrrolodihydroisoquinolines as PDE10 inhibitors | |
| ATE490244T1 (de) | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren | |
| MY134848A (en) | Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases | |
| WO2005012241A3 (en) | p-38 KINASE INHIBITORS | |
| NO20054082L (no) | Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander | |
| WO2004001059A3 (en) | Heterocyclic inhibitors of kinases | |
| YU42302A (sh) | Agonisti beta2-adrenergičnih receptora | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| MXPA05012596A (es) | Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol. | |
| IS2164B (is) | ß2-adrenvirk viðtaka gerandefni | |
| YU63202A (sh) | Derivati 2-okso-1-pirolidina, postupci za njihovo dobijanje i njihove upotrebe | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| TW200510380A (en) | Mitotic kinesin inhibitors | |
| ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
| MXPA05003640A (es) | Compuestos de dihidropiridina que tienen capacidad simultanea para bloquear los canales de calcio del tipo l y para inhibir la actividad de la fosfodiesterasa del tipo 3. | |
| WO2004050657A3 (en) | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | |
| TW200503710A (en) | Novel compounds | |
| WO2006060127A3 (en) | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | |
| WO2006007378A3 (en) | Pyrrolotriazine kinase inhibitors | |
| MXPA06010904A (es) | Inhibidores de pirazol cinasa triciclicos. | |
| MY146935A (en) | 4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | |
| NO20073113L (no) | Indenylderivater og anvendelse derav for behandling av neurologiske lidelser | |
| PH12021553257A1 (en) | Heterocyclic compounds for mediating tyrosine kinase 2 activity |